Generate Biomedicines (GENB) Stock Forecast: StockMap's 2-Week Call
GENB stock forecast: StockMap's model leans Underperform on Generate Biomedicines for the two weeks after the Nov 19 close, toward GENB trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 2 of 6 two-week windows on GENB since Aug 21; by chance, a call on the same dates was right 58% of the time.
Generate Biomedicines last closed at $10.37, -0.10% on the session.
Against the IVW growth benchmark the position is +2.23% over the forecast window.
Generate Biomedicines' market cap is $1.33B as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -42 (too close to call).
Where GENB sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 1 bullish and 14 bearish.
Agreement across those insights is 93%.
45 daily calls for GENB so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
Generate Biomedicines is classified under Health Care / Biotechnology.
StockMap tracks Generate Biomedicines as the 114th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Generate Biomedicines ranks 309th of 394 in the group, against a group median of -0.27.